New Small Molecule CN045 Drives Remyelination in Multiple Sclerosis Models
A phenotypic screen of 20,000 molecules identified CN045, a CNS-penetrable compound that promotes myelin repair with potency exceeding thyroid hormone T3.
Summary
Researchers at Cleveland Clinic screened 20,000 brain-targeted small molecules to find compounds that could repair myelin — the protective sheath around nerve fibers destroyed in multiple sclerosis. They identified CN045, a molecule that stimulates oligodendrocyte progenitor cells (the brain's myelin-making precursors) to mature and produce myelin at very low doses (40 nM), outperforming the thyroid hormone T3, a known benchmark compound. CN045 promoted myelin-like wrapping of artificial nanofibers by both mouse and human progenitor cells, and significantly boosted remyelination in mouse brains after chemically induced demyelination. The compound crosses the blood-brain barrier and shows low toxicity, though its short half-life in the body will require chemical refinement before clinical use.
Detailed Summary
Multiple sclerosis (MS) is a progressive neurological disease in which the immune system attacks myelin, the insulating sheath around nerve fibers essential for fast signal transmission. While existing MS therapies dampen immune attacks, none effectively restore lost myelin — leaving patients with accumulating disability. Remyelination therapy represents a critical unmet need in both MS management and broader neurological aging science.
Researchers at Cleveland Clinic and collaborating institutions conducted a phenotypic screen of 20,000 central-nervous-system-biased small molecules, testing each for its ability to drive mouse oligodendrocyte progenitor cells (OPCs) — the brain's dedicated myelin-repair cells — to differentiate into mature, myelin-producing oligodendrocytes. From this screen, they identified a lead compound, CN045, with an EC50 of 40 nM, making it significantly more potent than triiodothyronine (T3), the thyroid hormone previously used as a standard for OPC differentiation studies.
CN045 was validated across multiple experimental models. It promoted myelin-like ensheathment of engineered nanofibers by both mouse and human OPCs — an important translational step. In a mouse model of demyelination induced by cuprizone and rapamycin, CN045 significantly increased remyelination in both white and gray matter brain regions, demonstrating in vivo efficacy. Pharmacokinetic profiling confirmed CNS penetration and low cytotoxicity.
The primary limitation is CN045's short in vivo half-life, which reduces its immediate therapeutic utility. However, the authors note its chemical scaffold is well-suited to structural modifications that could improve metabolic stability. The study is also limited to preclinical animal and cell models; human clinical validation lies ahead.
For MS patients and the aging brain broadly, a pro-remyelination small molecule could help restore function lost to demyelination — a mechanism implicated in cognitive decline and motor deterioration with aging. CN045 represents a promising early-stage candidate worthy of further development.
Key Findings
- CN045 promotes OPC differentiation at 40 nM EC50, outperforming the thyroid hormone T3 benchmark.
- The compound significantly increased remyelination in both white and gray matter in a mouse demyelination model.
- CN045 promotes myelin-like wrapping of nanofibers by human OPCs, supporting translational relevance.
- CN045 penetrates the blood-brain barrier and shows low cytotoxicity in pharmacokinetic profiling.
- Short in vivo half-life is the main limitation, but the scaffold allows chemical optimization.
Methodology
Researchers screened 20,000 CNS-biased small molecules in a mouse OPC differentiation phenotypic assay, then validated the lead compound CN045 in engineered nanofiber myelin-ensheathment assays using mouse and human OPCs. In vivo remyelination efficacy was assessed in a cuprizone/rapamycin mouse demyelination model, with pharmacokinetic profiling conducted to assess CNS penetration and cytotoxicity.
Study Limitations
The study is based on preclinical mouse models and cell assays; human clinical efficacy and safety are unestablished. CN045's short in vivo half-life must be addressed through medicinal chemistry before clinical development is feasible. This summary is based on the abstract only, as the full text is not open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: